Clover Biopharmaceuticals Ireland Limited – Trademark Portfolio
Entity Type: 03
Clover Biopharmaceuticals Ireland Limited holds 6 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 6 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include CLOVER.
6th Floor, South Bank House
Dublin 4
Showing of trademarks Trademarks
Trademark Classifications
Clover Biopharmaceuticals Ireland Limited's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Clover Biopharmaceuticals Ireland Limited have?
Clover Biopharmaceuticals Ireland Limited has 6 U.S. trademarks filed with the USPTO. Of these, 6 registered.
What trademark classes does Clover Biopharmaceuticals Ireland Limited file in?
Clover Biopharmaceuticals Ireland Limited files trademarks across 2 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 42 covers scientific and technological services; industrial analysis and research services.
What are Clover Biopharmaceuticals Ireland Limited's most well-known trademarks?
Clover Biopharmaceuticals Ireland Limited's registered trademark portfolio includes well-known marks such as CLOVER. These are among 6 currently registered trademarks in the portfolio.
What is Clover Biopharmaceuticals Ireland Limited's trademark registration success rate?
Clover Biopharmaceuticals Ireland Limited has a 100% trademark registration rate, with 6 out of 6 resolved applications resulting in successful registration. Currently, 0 applications are pending review.